Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Low Breast Cancers”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT06000033
What this trial is testing

Study of Disitamab Vedotin and Anlotinib in Patients With HR-Negative, HER2-Low-Expressing Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Qilu Hospital of Shandong University 35
Not applicableStudy completedNCT07561346
What this trial is testing

Clinico-pathological and Genomic Features of HER2-low Early Breast Cancer

Who this might be right for
HER2-zero, HER2-low and HER2-positive Tumors Distribution Across HR Expression Categories
Hellenic Cooperative Oncology Group 3,648
Large-scale testing (Phase 3)Active Not RecruitingNCT06112379
What this trial is testing

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

Who this might be right for
Breast Cancer
AstraZeneca 1,902
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07151586
What this trial is testing

Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer

Who this might be right for
Triple Negative Breast NeoplasmsNeoplasm MetastasisHER 2 Low-expressing Breast Cancer
UNICANCER 260
Testing effectiveness (Phase 2)Looking for participantsNCT07661927
What this trial is testing

Skipping Hormone Therapy in Low-Risk Early Breast Cancer

Who this might be right for
Breast Cancer (Early Breast Cancer)
UNICANCER 700
Testing effectiveness (Phase 2)Ended earlyNCT00726180
What this trial is testing

Use of Trastuzumab to Induce Increased ER Expression in ER-negative/Low, Her-2/Neu Positive Breast Cancer

Who this might be right for
Breast Cancer
University of Michigan Rogel Cancer Center 1
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07618923
What this trial is testing

Neoadjuvant Dalpiciclib + AI → SHR-A1811 for HR+/HER2-Low Breast Cancer

Who this might be right for
Breast CancerHR Positive/HER2 Low Breast Cancer
Tang-Du Hospital 20
Post-approval studies (Phase 4)WithdrawnNCT03238703
What this trial is testing

Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer

Who this might be right for
HER2/Neu NegativeInvasive Breast CarcinomaPostmenopausal+2 more
Fred Hutchinson Cancer Center
Testing effectiveness (Phase 2)UnknownNCT05619016
What this trial is testing

[68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors

Who this might be right for
Esophageal NeoplasmsGastric Neoplasms MalignantBreast Cancer+1 more
Karolinska University Hospital 72
Testing effectiveness (Phase 2)Looking for participantsNCT05911958
What this trial is testing

SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer

Who this might be right for
HER2 Low Breast Carcinoma
Henan Cancer Hospital 66
Testing effectiveness (Phase 2)Active Not RecruitingNCT04443348
What this trial is testing

Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)

Who this might be right for
Triple Negative Breast CancerHormone Receptor Positive (HR+), HER2-negative Breast CancerBiopsy-proven, Positive Lymph Node(s)
Laura M. Spring, MD 120
Not applicableStudy completedNCT06040593
What this trial is testing

Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer

Who this might be right for
Hormone-receptor-positive Breast CancerHER2-low Breast CancerHER2-negative Breast Cancer
Daiichi Sankyo 927
Testing effectiveness (Phase 2)Looking for participantsNCT04553770
What this trial is testing

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

Who this might be right for
Early-stage Breast CancerHormone Receptor Positive Breast CarcinomaInvasive Breast Cancer+4 more
Jonsson Comprehensive Cancer Center 88
Large-scale testing (Phase 3)Looking for participantsNCT06492616
What this trial is testing

Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Who this might be right for
Breast Cancer
Stemline Therapeutics, Inc. 4,220
Early research (Phase 1)Ended earlyNCT02598427
What this trial is testing

Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer

Who this might be right for
HER2 Positive Untreated Metastatic Breast CancerAsymptomatic or Low Symptomatic Brain Metastasis in Breast Cancer
Kimberly Blackwell 1
Not applicableLooking for participantsNCT05466786
What this trial is testing

Distribution of the Homologous Recombination-related (HRR) Genesmutationsand HRD in Breast Cancer

Who this might be right for
Breast CancerHER2-low Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 255
Testing effectiveness (Phase 2)Ended earlyNCT02236572
What this trial is testing

Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score

Who this might be right for
Breast Cancer
Yale University 17
Not applicableLooking for participantsNCT06210776
What this trial is testing

Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)

Who this might be right for
HER2-positive Breast CancerHER2-low Breast CancerBreast Cancer+1 more
Daiichi Sankyo 800
Testing effectiveness (Phase 2)Looking for participantsNCT06642545
What this trial is testing

Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer

Who this might be right for
Breast Cancer
RemeGen Co., Ltd. 40
Early research (Phase 1)Ended earlyNCT02751528
What this trial is testing

QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer

Who this might be right for
Cancer
NantBioScience, Inc. 3
Next Page